Lung Forum 2026-2027
Accreditation Information
Target Audience
The target audience for this activity is medical oncology, radiation oncology, thoracic oncology, and thoracic surgical fellows and junior faculty actively involved in clinical research for patients with thoracic oncology.
Learning Objectives
- Evaluate the safety and efficacy of current and emerging therapeutic approaches for the treatment of patients with thoracic cancers, including modalities such as traditional chemotherapy, radiotherapy, surgery, molecularly targeted agents, immunotherapy, and others
- Identify strategies to enhance participation in clinical trials from both clinicians and patients with thoracic cancers in order to introduce novel agents into practice that improve the outcomes of patients with these malignancies
- Develop techniques to enhance communication and collaboration among multidisciplinary healthcare teams in order to optimize the outcomes of patients with thoracic cancers
- Assess strategies for the professional development of thoracic oncology fellows and junior faculty into leadership positions in oncology research and caring for patients with thoracic cancers
Accreditation
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Bio Ascend. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this live activity for 10.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosures
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
2026 Next Wave Faculty/Investigator Disclosures
Chairs/Faculty Mentors
Julie Brahmer, MD, MSc, FASCO
Consultant/Advisor/Speaker: Amgen, AstraZeneca, Bayer, BMS, Genentech/Roche, GSK, Foundation Medicine, Johnson & Johnson
Suresh Ramalingam, MD, FACP, FASCO
Research: Amgen, AstraZeneca, BMS, Merck, Pfizer
Shirish Gadgeel, MD
Consultant/Advisor/Speaker: AbbVie, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Genentech/Roche, Gilead, Pfizer, Regeneron
Consultant: Bayer
Ryan Gentzler, MD
Researcher: Amgen, AstraZeneca, Arrivent, BMS, Chugai, Daiichi Sankyo, Dizal, Janssen, Lilly, Merck, Nalo, Pfizer, Prelude Therapeutics, Puma, Takeda, Tempus,
Consultant/Advisor/Speaker: AbbVie, AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline
Ramaswamy Govindan, MD
No relevant financial relationships to disclose
Kristin Higgins, MD
Consultant/Advisor/Speaker: AstraZeneca, Daiichi Sankyo, Picture Health
Onkar Khullar, MD, MSc
No relevant financial relationships to disclose
Ticiana Leal, MD
Consultant/Advisor/Speaker: AbbVie, Amgen, AstraZeneca, BDT, Bristol Myers Squibb, Boehringer Ingelheim, Catalyst, Gilead, Johnson & Johson, Jazz Pharmaceuticals, Novocure, Merck, Molecular Partner Therapeutics, Naterra, Nuvation, Pfizer, Roche, Summit Therapeutics, Synthekine, Verastem
Mark Kris, MD
Consulting: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Merck, Pfizer
Taofeek Owonikoko, MD, PhD
Advisory Board: Amgen; AstraZeneca; Bayer; BeiGene, Bella Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Coherus Biosciences, Daiichi Sankyo, Eisai, EMD Serono, GenCART, Genentech, Gilead, GSK, Heat Biologics, Janssen, Jazz Pharmaceuticals, Lilly, Merck, Meryx, Novartis; Oncocyte, OncoHost, Puma Biosciences, Regeneron, Roche/Genentech, Inc., Takeda
Research Funding to Institution: Amgen Inc., AstraZeneca, Bayer Corporation, Bristol Myers Squibb, Cardiff Oncology, Inc., Eisai Inc., Roche/Genentech, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Oncorus, Inc., Pfizer, Turning Point Therapeutics, Inc., Y-mAbs Therapeutics, Inc, Daiichi Sankyo, Puma Biosciences, Cyclacel, GSK, Boehringer Ingelheim
Rachel Sanborn, MD
Consultant/Advisor/Speaker: AbbVie Oncology, AstraZeneca, Daiichi Sankyo, Gilead, Janssen Oncology/Johnson & Johnson, IDEology Health, PRIME Oncology, OncLive
Independent Consultant: Bio Ascend
Gary Teal, MBA
No relevant financial relationships to disclose
Investigators
Nikhila Aimalla, MBBS
No relevant financial relationships to disclose
Linda Albusoul, MD
No relevant financial relationships to disclose
Maroun Bou Zerdan, MD
No relevant financial relationships to disclose
Turja Chakrabarti, MD, MS
Consultant/Advisor/Speaker: Johnson & Johnson, MJH Life Sciences
Anusha Chidharla, MD
No relevant financial relationships to disclose
Lei Deng, MD
Consultant/Advisor/Speaker: Boehringer Ingelheim, Bristol Myers Squibb, Regeneron
Other (Institutional Research Funding): BillionToOne, BridgeBio Oncology Therapeutics, Bristol Myers Squibb, Merck, Solve Therapeutics, Daiichi Sankyo
Saumya Easaw, MD
No relevant financial relationships to disclose
Olivia Fankuchen, MD
Researcher: AZ Biotherapeutics
Dylan Fortman, MD
No relevant financial relationships to disclose
Arjan Gower, MD, MS
Consultant/Advisor/Speaker: AbbVie
Nehemias Guevara Rodriguez, MD
No financial relationships to disclose
Lee Hong, MD, PhD
No relevant financial relationships to disclose
Rachel Keogh, MBBChBAO
Other (Travel): MSD/Merck
Jongmyung Kim, MD, PhD
No relevant financial relationships to disclose
Mumtu Lalla, MD
No relevant financial relationships to disclose
Daniel Li, MD, PhD
No relevant financial relationships to disclose
Jennifer Li, MD
No relevant financial relationships to disclose
Yuchen Li, MD
Consultant/Advisor/Speaker: AstraZeneca, Merck, Pfizer
Julian Marin-Acevedo, MD
Consultant/Advisor/Speaker: Merus, OncLive
Yunan Nie, MD
No relevant financial relationships to disclose
Christopher Pallas, MD
Researcher: Janssen Research and Development, Summit Therapeutics
William Phillips, MD
No relevant financial relationships to disclose
Fernando Pikabea Diaz, MD
No relevant financial relationships to disclose
Dena Rhinehart, MD
Consultant/Advisor/Speaker: Johnson & Johnson
Guilherme Sacchi de Camargo, MD
No relevant financial relationships to disclose
Shrey Sindhwani, MD
No relevant financial relationships to disclose
Noha Soror, MD
No relevant financial relationships to disclose
Arthi Sridhar, MD
Consultant/Advisor/Speaker: AstraZeneca, Johnson & Johnson, Nuvation Bio
Berenice Scarlet Urtecho Suarez, MD
No relevant financial relationships to disclose
Teja Voruganti, MD
No relevant financial relationships to disclose
Brittney Williams, MD
No relevant financial relationships to disclose
Instructions for Credit
To receive CE credit, learners must follow these steps:
- Visit https://cme.partnersed.com/NextWaveLung2026
- Complete the activity evaluation
- Upon completion of all evaluation questions, your credit will be made available for download immediately.